

In This Issue

- Project news
- Keynote
- Achievements
- Publications
- Report-o-meter
- Upcoming Events

eTOX in a nutshell: the eTOX flyer



This summer, the eTOX flyer has been designed. It was composed to briefly describe the background of the project, their aims, the general workflow of activities, and the most remarkable achievements reached up to date.

From now on, eTOX partners will start to distribute it as part of the project dissemination plan.

PROJECT NEWS

EFPIA-only meeting, Frankfurt, Germany

In the light of the forthcoming end of the first project phase (excluding ENSO) the Executive Committee of eTOX invited the EFPIA partners for an assessment of the eTOX project achievements at Sanofi, September 18th. The partners valued the unprecedented endeavor of eTOX database, though user friendliness allowing routine application still needs improvement. It was also identified that the process of model development needs a stronger joint effort by both EFPIA and public partners. Ways to achieve this were identified and will be implemented early 2015.

eTOX at the 9th World Congress on Alternatives and Animal Use in the Life Sciences, Prague, Czech Republic

The eTOX project was presented in this important forum, August 25-28th, under the aspect of contributions to 3R ("Can data sharing in the pharmaceutical industry contribute to 3R?"). Interest was expressed by cosmetic industries to collaborate with eTOX, since safety assessment for new cosmetic ingredients has to rely exclusively on *in vitro* data or existing data sources.

KEYNOTE

About PPPs and critical success factors

Message from Carlos Diaz, Synapse CEO & eTOX Project Manager

By definition, any Innovative Medicine Initiative (IMI) project is a Public-Private Partnership (PPP). As such, it bears the potential to reveal (and, indeed, seems to address) the traditional academia-industry 'divide' in all of its glory: flexible objectives *vs* specific practical targets; individual names *vs* company names; flexible time schedule *vs* constant time pressure; etc.



Yet, in the end, the challenging adventure of IMI projects has taught me that perhaps PPP should instead stand for something different: Project-Plan-People. **Project** for the idea, the initial spark that puts tens of institutions in motion towards an often game-changing goal – our intended destination. **Plan** because how you configure the project design, the components and the interfaces between them is your key map to that destination. An ever-changing map quite often, for an ever-changing weather... And, from the management perspective, I have no doubt that **People** are the most critical success factor: what really drives the project forward is the endless hours, the discussions, the fears, the pride, the capacity to adapt, correct, challenge and innovate of the hundreds of individuals that are part of what we now call **eTOX**. It is not therefore about how you tag institutions (public or private); it is about how you manage incentives, needs and expectations of people involved, and how they can relate to the project.

Some may argue that resources are your fourth power, the vehicle to get you to your destination. But, truth be said, I have seen good ideas and good people travel very far with poor resources – so I am inclined to think that it can just modulate the speed of your trip.


Back home today after a very good **eTOX** meeting, I cannot help being grateful for the many people that, after almost five years of gains and losses, despite uncertainty and ever-growing question marks, still have the resolution to propose, solve, help and listen, still have faith in what we are trying to achieve – making my job as project manager a lot easier. *People that transcend their individual personality and interests to contribute as much as they can to the whole.* And I cannot help thinking that, with these People, the eTOX 'PPP' can only be a huge success.




ACHIEVEMENTS

- Mid August 2014, Lhasa Limited launched the **ninth release of the Vitic Nexus eTOX database**, with 1,403 substances (515 as confidential) linked to 4,291 study records contributed by all EFPIA partners of the eTOX consortium. In addition, it contains data from ChEMBL database (224,824 substances and 847,222 records), and data of 669 substances and 272,940 records from public toxicology related databases (TG-GATES and DrugMatrix).
- Following a review of existing database schema and test guidelines, a set of questions were put to the reconvened schema sub-group (representatives from Bayer, GSK and Lundbeck) for extending the schema to capture data of carcinogenicity, reproductive/developmental and safety pharmacology studies (cardiovascular, CNS and pulmonary effects). This allows data collection to commence and will be implemented in the database release due January 2015.
- To accommodate external data requests to access **eTOX database**, the project has developed a **Data Access Strategy**: External requesters describe their interest and the desired data; this request is transferred to the eTOX data access officer, who analyzes the confidentiality status of the requested data sets; subsequently, an internal scientific review resulting in a recommendation (Recomm) is performed, and the result of this recommendation (yes/no) is forwarded to the data access officer who then informs the data owners accordingly; eventually, the final decision lies in the hands of the data owner, who then either performs the query or transfers the requested data.

Vitic Nexus eTOX database 2014.2




Data Access Strategy



REPORT-O-METER

6416

Currently, 4642 reports of the 6416 cleared for sharing within the consortium have finished the extraction data process and are available in the **Vitic Nexus eTOX database**.



Cleared Reports submitted to CROs or in-house facilities for data extraction
Extracted Reports with processing by CROs or in-house facilities completed
Vitic Reports with data available at Vitic Nexus database

PUBLICATIONS

A full list of publications is available on <http://www.etoxproject.eu>

- ARTICLE-(UNIVIE): [Exploiting Open Data: A new era in pharmacoinformatics](#). Goldmann D, Montanari F, Richter L, Zdrzil B, Ecker GF. *Future Med Chem* 2014;6(5):503-14.
- ARTICLE-(UNIVIE): [BCRP inhibition: from data collection to ligand-based modeling](#). Montanari F, Ecker GF. *Mol Inf* 2014;33:322-31.
- PRESENTATION-(FIMIM): Sanz F. eTOX: integrative strategies for predicting drug toxicities. EuroQSAR 2014

UPCOMING EVENTS

- **19-22.10.14** | Safety Pharmacology Society 14th Annual Meeting. Washington DC, (USA). Info: <http://goo.gl/FEFT3s>.
- **09-12.11.14** | American College of Toxicology 35th Annual Meeting. Orlando, Florida (USA). Info: <http://goo.gl/Y6kk2j>.
- **10-11.11.14** | In Vitro Toxicology Society, AstraZeneca. Cheshire (UK). Info: <http://www.ivts.org.uk/site/ivts2014/>.
- **27.11.14** | Animal Replacement Science 2014: Improving relevance to human disease-challenges, innovations and applications. London (UK). Info: <http://www.animalreplacementscience.com>.